NT_1170x120_1-11-18

generic drugs

FDA acts to boost Rx drug competition

FDA acts to boost Rx drug competition

WASHINGTON — The Food and Drug Administration today announced two new steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of

Generic drugs see low abandonment rate

Generic drugs see low abandonment rate

WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly

Savings from generic drugs edge up

Savings from generic drugs edge up

WASHINGTON — Annual health care savings from generic prescription drugs rose nearly 10% last year to $227 billion, according to the Generic Pharmaceutical Association (GPhA). GPhA’s 2016 Generic Drug Savings and Access in the United States report, released Wednesday, tallied the 10-year national savings for generics at $1.46 trillion, representing a gain of 328% from

Trump, Clinton part ways on health care policy

Trump, Clinton part ways on health care policy

NEW YORK — With the 2016 presidential election drawing near, health care has emerged as a policy area in which the two major candidates’ differences are strikingly clear. A useful starting point might be their respective approaches to prescription drug pricing. The Republican candidate, Donald Trump, created a sensation in January when he advocated allowing

FDA pushes back generic drug labeling rule

FDA pushes back generic drug labeling rule

WASHINGTON — The Food and Drug Administration is again postponing the release of a final rule that would change generic drug labeling requirements. In a Federal Register notice this week, the FDA indicated that it aims to implement the final rule in April 2017, though many industry stakeholders had expected the agency to do so

FDA works to speed generic drug approvals

FDA works to speed generic drug approvals

WASHINGTON — Amid calls for a quicker approval process, the Food and Drug Administration last year cleared for market the most generic drug products in its history. The FDA said it approved or issued tentative approvals for more than 700 generic drugs in 2015. The announcement may help to blunt criticism from some federal legislators

Teva hatches plans for new global brand

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has begun an enterprisewide corporate identity program to build a global brand. Teva said Wednesday that it will introduce and implement the new brand within the company over the next 12 months. The company noted that it plans to unveil the brand to its 43,000 employees worldwide before

GPhA tabs Mylan’s Bresch to chair board

GPhA tabs Mylan’s Bresch to chair board

ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,

Generics resonate with consumers

NEW YORK — Americans prefer generic drugs to brands for both prescription and over-the-counter drugs, according to a new Harris Poll. Among those who purchase prescription drugs for themselves, nearly seven in 10 (69%) say, given a choice, they would opt for generics more often. Three in 10 go as far as saying they would

GPhA tallies savings from generic drug use

GPhA tallies savings from generic drug use

WASHINGTON — The U.S. health care system saved a record $254 billion last year through the use of lower-cost generic drugs, the Generic Pharmaceutical Association (GPhA) reports. Over the past decade, covering 2005 to 2014, the savings yielded by the use of generics over their more expensive brand-name counterparts totals $1.68 trillion, according to the

Global consolidation rolls on in drug channel

Global consolidation rolls on in drug channel

McKesson’s deal to buy Ireland’s UDG Healthcare reflects the global consolidation of health care distribution, as drug wholesalers continue their drive for scale, especially in the realm of generic drugs, according to Fitch Ratings. “The UDG deal will add to McKesson’s generic purchasing power and further enhance its European pharmaceutical distribution presence, following its acquisition

Amneal forms biosciences unit

Amneal forms biosciences unit

BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has formed Amneal Biosciences, a new business unit. Amneal said Tuesday that the new subsidiary will focus exclusively on the commercialization of high-barrier-to-entry generic drugs and specialty pharmaceuticals — such as injectables, oncologics and biosimilars — health care providers worldwide. “Having a dedicated company focused on the unique needs and

GPhA tabs Davis as new CEO

GPhA tabs Davis as new CEO

WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in